Halozyme Therapeutics (HALO)
(Real Time Quote from BATS)
$39.16 USD
+0.19 (0.49%)
Updated Apr 24, 2024 03:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Income Statements
Fiscal Year end for Halozyme Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 829 | 660 | 443 | 268 | 196 |
Cost Of Goods | 192 | 139 | 81 | 43 | 46 |
Gross Profit | 637 | 521 | 362 | 224 | 150 |
Selling & Adminstrative & Depr. & Amort Expenses | 299 | 253 | 86 | 80 | 218 |
Income After Depreciation & Amortization | 338 | 268 | 276 | 144 | -68 |
Non-Operating Income | 30 | -2 | -20 | 5 | 7 |
Interest Expense | 19 | 17 | 8 | 20 | 12 |
Pretax Income | 348 | 249 | 249 | 129 | -72 |
Income Taxes | 67 | 47 | -154 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 282 | 202 | 403 | 129 | -72 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 282 | 202 | 403 | 129 | -72 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 423 | 326 | 285 | 163 | -64 |
Depreciation & Amortization (Cash Flow) | 86 | 59 | 9 | 18 | 4 |
Income After Depreciation & Amortization | 338 | 268 | 276 | 144 | -68 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 134.20 | 140.61 | 146.80 | 141.46 | 144.33 |
Diluted EPS Before Non-Recurring Items | 2.50 | 2.08 | 1.86 | 0.91 | -0.50 |
Diluted Net EPS (GAAP) | 2.10 | 1.44 | 2.74 | 0.91 | -0.50 |
Fiscal Year end for Halozyme Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 230.04 | 216.03 | 221.04 | 162.14 |
Cost Of Goods | NA | 52.30 | 54.82 | 50.07 | 35.17 |
Gross Profit | NA | 177.74 | 161.21 | 170.97 | 126.97 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 76.71 | 72.93 | 76.52 | 73.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 101.03 | 88.28 | 94.45 | 53.79 |
Non-Operating Income | NA | 5.36 | 17.99 | 3.19 | 2.98 |
Interest Expense | NA | 5.22 | 4.51 | 4.49 | 4.54 |
Pretax Income | NA | 101.18 | 101.76 | 93.16 | 52.24 |
Income Taxes | NA | 15.79 | 19.92 | 18.40 | 12.62 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 85.39 | 81.84 | 74.75 | 39.62 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 85.39 | 81.84 | 74.75 | 39.62 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 131.04 | 134.08 | 133.54 | 137.90 |
Diluted EPS Before Non-Recurring Items | NA | 0.75 | 0.69 | 0.68 | 0.43 |
Diluted Net EPS (GAAP) | NA | 0.64 | 0.61 | 0.56 | 0.29 |